Walleye Capital’s BIOATLA INC BCAB Stock Holding History

Walleye Capital’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,407	Closed	-$852K	–	2361
2022 Q1	$852K	Buy	+3,407	New	+$1.43M	0.02%	714

Other funds holding BCAB

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Walleye Capital's BCAB Position: Q2 2022 in Review

Walleye Capital sold out of BIOATLA INC (BCAB) in Q2 2022, closing a stake of 3,407 shares — an estimated $852K sold.

Walleye Capital first reported a position in BCAB in Q1 2022 and held it in 1 quarter. The position peaked at $852K in Q1 2022. 76 funds tracked by Wall St. Rank hold BCAB as of Q2 2022.

Walleye Capital reported no remaining BIOATLA INC position as of Q2 2022 after selling out during the quarter.
Walleye Capital sold 3,407 BIOATLA INC shares in Q2 2022, an estimated $852K.
Walleye Capital first reported a position in BIOATLA INC in Q1 2022 and held it in 1 quarter.
Walleye Capital's BIOATLA INC position peaked at $852K in Q1 2022.
76 funds tracked by Wall St. Rank held BIOATLA INC as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.